Investors Research Corp’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $122K | Buy |
+642
| New | +$121K | 0.02% | 310 |
|
|
2026
Q1 | – | Sell |
-1,240
| Closed | -$228K | – | 853 |
|
|
2025
Q4 | $228K | Hold |
1,240
| – | – | 0.04% | 280 |
|
|
2025
Q3 | $190K | Buy |
1,240
+110
| +10% | +$16.6K | 0.04% | 307 |
|
|
2025
Q2 | $158K | Hold |
1,130
| – | – | 0.03% | 331 |
|
|
2025
Q1 | $166K | Buy |
1,130
+120
| +12% | +$17.4K | 0.04% | 316 |
|
|
2024
Q4 | $132K | Hold |
1,010
| – | – | 0.03% | 354 |
|
|
2024
Q3 | $157K | Hold |
1,010
| – | – | 0.03% | 340 |
|
|
2024
Q2 | $158K | Sell |
1,010
-577
| -36% | -$86.8K | 0.04% | 339 |
|
|
2024
Q1 | $215K | Sell |
1,587
-392
| -20% | -$51.9K | 0.05% | 312 |
|
|
2023
Q4 | $267K | Buy |
1,979
+192
| +11% | +$25K | 0.06% | 285 |
|
|
2023
Q3 | $242K | Hold |
1,787
| – | – | 0.06% | 296 |
|
|
2023
Q2 | $256K | Sell |
1,787
-1,200
| -40% | -$177K | 0.06% | 298 |
|
|
2023
Q1 | $415K | Sell |
2,987
-350
| -10% | -$47.1K | 0.11% | 235 |
|
|
2022
Q4 | $452K | Hold |
3,337
| – | – | 0.12% | 219 |
|
|
2022
Q3 | $366K | Buy |
3,337
+15
| +0.5% | +$1.9K | 0.11% | 226 |
|
|
2022
Q2 | $439K | Hold |
3,322
| – | – | 0.13% | 213 |
|
|
2022
Q1 | $441K | Hold |
3,322
| – | – | 0.12% | 210 |
|
|
2021
Q4 | $387K | Hold |
3,322
| – | – | 0.12% | 215 |
|
|
2021
Q3 | $399K | Buy |
3,322
+322
| +11% | +$37.5K | 0.13% | 204 |
|
|
2021
Q2 | $359K | Hold |
3,000
| – | – | 0.12% | 219 |
|
|
2021
Q1 | $298K | Hold |
3,000
| – | – | 0.11% | 245 |
|
|
2020
Q4 | $300K | Hold |
3,000
| – | – | 0.12% | 241 |
|
|
2020
Q3 | $329K | Hold |
3,000
| – | – | 0.16% | 190 |
|
|
2020
Q2 | $317K | Hold |
3,000
| – | – | 0.16% | 200 |
|
|
2020
Q1 | $268K | Hold |
3,000
| – | – | 0.17% | 210 |
|
|
2019
Q4 | $299K | Sell |
3,000
-833
| -22% | -$78.4K | 0.14% | 230 |
|
|
2019
Q3 | $342K | Hold |
3,833
| – | – | 0.17% | 182 |
|
|
2019
Q2 | $316K | Sell |
3,833
-150
| -4% | -$11.8K | 0.17% | 187 |
|
|
2019
Q1 | $322K | Hold |
3,983
| – | – | 0.17% | 180 |
|
|
2018
Q4 | $303K | Hold |
3,983
| – | – | 0.21% | 179 |
|
|
2018
Q3 | $315K | Hold |
3,983
| – | – | 0.18% | 200 |
|
|
2018
Q2 | $280K | Hold |
3,983
| – | – | 0.16% | 217 |
|
|
2018
Q1 | $279K | Hold |
3,983
| – | – | 0.17% | 225 |
|
|
2017
Q4 | $276K | Buy |
+3,983
| New | +$269K | 0.17% | 217 |
|
Other funds holding AZN
EP
IA
Investors Research Corp's AZN Position: Q2 2026 in Review
Investors Research Corp opened a new position in AstraZeneca (AZN) in Q2 2026: 642 shares worth $122K. The stake represents 0.02% of the portfolio and ranks #310 among its holdings. This is a return to the name: Investors Research Corp previously reported a position in AZN as recently as Q4 2025.
Investors Research Corp first reported a position in AZN in Q4 2017 and has held it in 34 quarters since. The position peaked at $452K in Q4 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Investors Research Corp held 642 shares of AstraZeneca worth $122K as of Q2 2026.
- AstraZeneca was a new Investors Research Corp position in Q2 2026.
- AstraZeneca made up 0.02% of Investors Research Corp's portfolio in Q2 2026, its #310 holding.
- Investors Research Corp first reported a position in AstraZeneca in Q4 2017 and has held it in 34 quarters since.
- Investors Research Corp's AstraZeneca position peaked at $452K in Q4 2022.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.